Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Ustekinumab effective for IBD with concomitant psoriasis, psoriatic arthritis

03 Jul 2019
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Ustekinumab, delivered subcutaneously, is effective for patients with inflammatory bowel disease (IBD) receiving concomitant treatment for dermatological or rheumatological conditions, a recent study has found.

Researchers conducted a multicentre, retrospective analysis of 70 IBD patients (median age, 41.75 years; 45 percent female; 91.4 percent Crohn’s disease) who were initiated on ustekinumab for concomitant active psoriasis or psoriatic arthritis. The primary study endpoint was overall persistence of ustekinumab, defined as therapy maintenance due to sustained clinical benefit.

The median time on ustekinumab was 10.7 months. Twelve patients (17.1 percent) withdrew from the medication, all of whom had CD. Median time to withdrawal was 7.4 months. Half of the withdrawals were due to the lack of benefit for the skin or joint disease, four due to lack of benefit for IBD, and two due to adverse events.

At baseline, 56 patients had active disease. At the last follow-up after ustekinumab treatment, majority of these participants (60.7 percent; n=34) were in clinical remission. The cumulative probabilities of achieving remission at 6 and 9 months were 84.7 percent and 63.9 percent, respectively.

Disaggregating according to comorbid conditions did not meaningfully change the results. Ustekinumab induced clinical remission in majority of patients with either psoriasis (82.2 percent; 37 of 45) or psoriatic arthritis (60 percent; 15 of 25).

Ustekinumab likewise had a favourable safety profile. Only 10 cases of adverse events were reported in nine participants. Three adverse events needed emergency care: acute intestinal obstruction, dehydration due to acute gastroenteritis and acute renal colic.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.